Patents by Inventor Aron Brandon JAFFE,

Aron Brandon JAFFE, has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR EPIGENETIC REGULATION OF HBV GENE EXPRESSION
    Publication number: 20240132855
    Abstract: This invention relates to compositions, methods, strategies, and treatment modalities related to the epigenetic modification of hepatitis B virus (HBV) genes.
    Type: Application
    Filed: September 25, 2023
    Publication date: April 25, 2024
    Inventors: Aron Brandon Jaffe, Noorussahar Abubucker, Yesseinia Anglero-Rodriguez, Vic Myer, Angelo Leone Lombardo, Martino Alfredo Cappelluti
  • Notch2 binding molecules for treating respiratory diseases
    Patent number: 9944700
    Abstract: The balance and distribution of epithelial cell types is required to maintain tissue homeostasis. In the lung, perturbations of this balance are hallmarks of human respiratory diseases, including goblet cell metaplasia and enhanced mucus secretion in asthma and chronic obstructive pulmonary disease. We found that inflammatory cytokine treatment resulted in a skewing of basal cell differentiation towards a goblet cell fate, culminating in enhanced mucus production. We identified Notch2 as a key node required for cytokine-induced goblet cell metaplasia in vitro and in vivo Inhibition of Notch2 prevents goblet cell metaplasia induced by a broad range of stimuli, which is a hallmark of many respiratory diseases.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: April 17, 2018
    Assignee: NOVARTIS AG
    Inventors: Henry Luke Danahay, Aron Brandon Jaffe
  • NOTCH2 BINDING MOLECULES FOR TREATING RESPIRATORY DISEASES
    Publication number: 20160046710
    Abstract: The balance and distribution of epithelial cell types is required to maintain tissue homeostasis. In the lung, perturbations of this balance are hallmarks of human respiratory diseases, including goblet cell metaplasia and enhanced mucus secretion in asthma and chronic obstructive pulmonary disease. We found that inflammatory cytokine treatment resulted in a skewing of basal cell differentiation towards a goblet cell fate, culminating in enhanced mucus production. We identified Notch2 as a key node required for cytokine-induced goblet cell metaplasia in vitro and in vivo Inhibition of Notch2 prevents goblet cell metaplasia induced by a broad range of stimuli, which is a hallmark of many respiratory diseases.
    Type: Application
    Filed: March 11, 2014
    Publication date: February 18, 2016
    Applicant: NOVARTIS AG
    Inventors: Henry Luke DANAHAY, Aron Brandon JAFFE,